Durata Therapeutics is moving its base from New Jersey to Chicago, "a fertile recruiting ground for us," CEO Paul Edick said. The company is preparing the send dalbavancin for review by the FDA as a weekly IV antibiotic.
Published in Brief:
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan